These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11064513)

  • 1. Lipodystrophy and nucleoside analogue therapy in HIV-infected patients: important question, few valid answers.
    Savès M; Chêne G; Suissa S
    J Acquir Immune Defic Syndr; 2000 Sep; 25(1):96-7. PubMed ID: 11064513
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipodystrophy and long-term therapy with nucleoside reverse transcriptase inhibitors.
    Moreno S; Martínez E
    AIDS; 2000 May; 14(7):905-6. PubMed ID: 10839605
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete reversibility of severe nucleoside-induced lipodystrophy.
    Strobel M; Muller P; Claudel P
    AIDS; 1999 Dec; 13(18):2606-7. PubMed ID: 10630538
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV lipodystrophy: a review.
    Kravcik S
    HIV Clin Trials; 2000; 1(3):37-50. PubMed ID: 11590504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
    Aldeen T; Wells C; Hay P; Davidson F; Lau R
    AIDS; 1999 May; 13(7):865-7. PubMed ID: 10357391
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy.
    Saint-Marc T; Touraine JL
    AIDS; 1999 Oct; 13(15):2188-9. PubMed ID: 10546885
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Leading to lipodystrophy.
    TreatmentUpdate; 2007 Feb; 19(2):3-4. PubMed ID: 17447312
    [No Abstract]   [Full Text] [Related]  

  • 10. Report from the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.
    Confrancesco J
    Hopkins HIV Rep; 2003 Jan; 15(1):4-5. PubMed ID: 12542003
    [No Abstract]   [Full Text] [Related]  

  • 11. Complications & side effects. Nukes and fat wasting.
    TreatmentUpdate; 2004; 16(7):3-4. PubMed ID: 17225282
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipodystrophy update--the continuing saga.
    Proj Inf Perspect; 2001 Mar; (32):9-10. PubMed ID: 11682779
    [No Abstract]   [Full Text] [Related]  

  • 13. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen.
    Leitz G; Robinson P
    AIDS; 2000 Mar; 14(4):468-9. PubMed ID: 10770555
    [No Abstract]   [Full Text] [Related]  

  • 14. A case of lipodystrophy after the initiation of zidovudine, lamivudine and efavirenz in an asymptomatic HIV-1-infected patient.
    Rickerts V; Bickel M; Tews J; Jacobi V; Staszewski S
    HIV Med; 2000 Jul; 1(3):164-5. PubMed ID: 11737346
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipodystrophy--introduction.
    TreatmentUpdate; 2001; 13(7):2-3. PubMed ID: 11794857
    [No Abstract]   [Full Text] [Related]  

  • 16. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
    Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
    AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on fat.
    TreatmentUpdate; 2002 Nov; 14(8):4. PubMed ID: 12501822
    [No Abstract]   [Full Text] [Related]  

  • 18. Efavirenz-associated breast hypertrophy in HIV-infection patients.
    Mercié P; Viallard JF; Thiébaut R; Faure I; Rispal P; Leng B; Pellegrin JL
    AIDS; 2001 Jan; 15(1):126-9. PubMed ID: 11192857
    [No Abstract]   [Full Text] [Related]  

  • 19. Face to face with lipoatrophy. An interview with David Nolan by Nelson Vergel.
    Nolan D
    GMHC Treat Issues; 2005; 19(3-4):1-6. PubMed ID: 16003843
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-HIV agents. Efavirenz and fat wasting--what might be happening?
    TreatmentUpdate; 2007 Feb; 19(2):7-8. PubMed ID: 17447315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.